Amuvatinib Uses, Dosage, Side Effects and more
Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.
| Attribute | Details |
|---|---|
| Trade Name | Amuvatinib |
| Generic | Amuvatinib |
| Amuvatinib Other Names | Amuvatinib |
| Type | |
| Formula | C23H21N5O3S |
| Weight | Average: 447.51 Monoisotopic: 447.13651073 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.
Elimination Route
Orally available
